These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2568172)

  • 1. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression.
    Harker WG; Slade DL; Dalton WS; Meltzer PS; Trent JM
    Cancer Res; 1989 Aug; 49(16):4542-9. PubMed ID: 2568172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone.
    Dalton WS; Cress AE; Alberts DS; Trent JM
    Cancer Res; 1988 Apr; 48(7):1882-8. PubMed ID: 2894893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells.
    Nakagawa M; Schneider E; Dixon KH; Horton J; Kelley K; Morrow C; Cowan KH
    Cancer Res; 1992 Nov; 52(22):6175-81. PubMed ID: 1358431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
    Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein.
    Haber M; Norris MD; Kavallaris M; Bell DR; Davey RA; White L; Stewart BW
    Cancer Res; 1989 Oct; 49(19):5281-7. PubMed ID: 2569932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased P-glycoprotein expression in multidrug-sensitive and -resistant human myeloma cells induced by the cytokine leukoregulin.
    Evans CH; Baker PD
    Cancer Res; 1992 Nov; 52(21):5893-9. PubMed ID: 1356622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
    Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.
    Mirski SE; Gerlach JH; Cole SP
    Cancer Res; 1987 May; 47(10):2594-8. PubMed ID: 2436751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
    Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.
    Politi PM; Sinha BK
    Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate.
    Arkin H; Ohnuma T; Kamen BA; Holland JF; Vallabhajosula S
    Cancer Res; 1989 Dec; 49(23):6556-61. PubMed ID: 2573416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
    Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
    Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS; Danks MK; Schmidt CA; Beck WT
    Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
    Hill AB; Beck WT; Trent JM
    Cancer Res; 1988 Jan; 48(2):393-8. PubMed ID: 2891436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA.
    Harker WG; Sikic BI
    Cancer Res; 1985 Sep; 45(9):4091-6. PubMed ID: 4028002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
    Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.
    Gutierrez PL; Wilder PJ; Biswal N
    Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
    Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and characterization of a human myelogenous leukemia cell line resistant to 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide.
    Beran M; Andersson BS
    Cancer Res; 1987 Apr; 47(7):1897-904. PubMed ID: 3469023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.